NUCLEIC ACID DETECTION USING TYPE III CRISPR COMPLEX

    公开(公告)号:US20240182988A1

    公开(公告)日:2024-06-06

    申请号:US18331811

    申请日:2023-06-08

    摘要: The disclosure relates to engineered systems and methods for detecting target nucleic acid in a sample, which may be a complex mixture. The systems and methods may improve sensitivity of target nucleic acid detection by enhancing signal generation. For example, signal generation may be enhanced through programmable capture and concentration of the target nucleic acid using an engineered type III CRISPR complex. Various ancillary nucleases such as Can1, Can2, and NucC are identified and may be used for detection. For example, binding of the engineered type III CRISPR complex may produce products that activate the identified ancillary nucleases. Different activators trigger changes in the substrate specificity of these nucleases. The activated nucleases may be used to detect programmatic detection of the target nucleic in the sample. The systems and methods are shown to detect viral RNA directly from nasopharyngeal swab samples.

    NUCLEIC ACID DETECTION USING TYPE III CRISPR COMPLEX

    公开(公告)号:US20230053573A1

    公开(公告)日:2023-02-23

    申请号:US17814097

    申请日:2022-07-21

    IPC分类号: C12Q1/70

    摘要: The disclosure relates to engineered systems and methods for detecting target nucleic acid in a sample, which may be a complex mixture. The systems and methods may improve sensitivity of target nucleic acid detection by enhancing signal generation. For example, signal generation may be enhanced through programmable capture and concentration of the target nucleic acid using an engineered type III CRISPR complex. Various ancillary nucleases such as Can1, Can2, and NucC are identified and may be used for detection. For example, binding of the engineered type III CRISPR complex may produce products that activate the identified ancillary nucleases. Different activators trigger changes in the substrate specificity of these nucleases. The activated nucleases may be used to detect programmatic detection of the target nucleic in the sample. The systems and methods are shown to detect viral RNA directly from nasopharyngeal swab samples.

    MICROSCOPE LENS WITH INTEGRATED WIDE-FIELD CAMERA AND BEAM SCANNING DEVICE

    公开(公告)号:US20220244517A1

    公开(公告)日:2022-08-04

    申请号:US17717774

    申请日:2022-04-11

    摘要: A device for viewing a target, the device including a housing, an objective lens positioned within the housing, where the objective lens has a first lens group including at least a first lens and a second lens group including at least a second lens, the first lens positioned closer to the target than the second lens, and a camera positioned within the objective lens between the first lens and the second lens, where the camera is configured to provide images of the target located near a focal point of the objective lens, and wherein the arrangement of the first lens, the second lens, and the camera provides for simultaneous capture of a first image of a surface of the target and a second image of a sub-surface cellular structure of the target.

    ENGINEERED CRISPR-CAS SYSTEMS AND METHODS FOR SENSITIVE AND SPECIFIC DIAGNOSTICS

    公开(公告)号:US20210332446A1

    公开(公告)日:2021-10-28

    申请号:US17240858

    申请日:2021-04-26

    IPC分类号: C12Q1/70 C12N9/22 C12N15/11

    摘要: The disclosure relates to an engineered type III CRISPR-Cas system for sensitive and sequence specific detection of nucleic acid in a sample. For example, the engineered type III CRISPR-Cas system may be implemented as an assay for testing SARS-CoV-2 virus (or other target nucleic acid in the sample) that can be performed quickly, such as in one hour or less. Nucleic acid recognition by type III systems may trigger Cas10-mediated nuclease activity and/or polymerase activity, which may generate pyrophosphates, protons and cyclic oligonucleotides. The nuclease activity and/or the one or more products of the Cas10-polymerase are detected using colorimetric, visible fluorometric, and/or instrumented fluorometric detection.

    BIOMARKERS FOR DIAGNOSIS AND MANAGEMENT OF NEURO-IMMUNOLOGICAL DISEASES

    公开(公告)号:US20190265254A1

    公开(公告)日:2019-08-29

    申请号:US16284914

    申请日:2019-02-25

    IPC分类号: G01N33/68

    摘要: Biomarkers associated with neuroimmunological disease are described. The disclosed biomarkers are secreted proteins identified in cerebral spinal fluid (CSF) samples of patients with neurological disease. The disclosed biomarkers identify patients with intrathecal inflammation, distinguish multiple sclerosis (MS) patients from patients with other types of inflammatory neurological diseases and from subjects without MS, distinguish progressive MS patients from patients with relapsing-remitting MS, identify subjects with non-MS inflammatory neurological diseases, differentiate healthy subjects from patients with any type of neurological disease, and/or identify subjects with increased disability, CNS tissue damage and/or neurodegeneration. Process-specific biomarkers that can be used in place of a brain biopsy to identify immune cell infiltration and/or activation in the CNS are also described. Methods of treating subject with neurological disease, and methods of evaluating the efficacy of particular treatments, based on detection of the disclosed biomarkers are also described.